CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
CARDIMMUN focuses on developing a diagnostic test and a monoclonal antibody to reduce cardiovascular disease risks. It aims to personalize treatment for patients with low anti-phosphorylcholine levels, integrating preclinical and clinical studies to advance towards market readiness.
The project, CARDIMMUN, aims to pursue development of the scientific findings from the FP6 project CVDImmune.
Based on our patented discovery, that low levels of anti-PC (phosphorylcholine) indicate risk for future development of cardiovascular disease, we have developed both a diagnostic test (a marker to identify cardiovascular disease patients that are at high risk of secondary events) and a candidate drug - an innovative fully human monoclonal antibody antibody, PC-mAb - that can block vascu…
Leiden University Medical Center
ACADEMISCH ZIEKENHUIS LEIDEN
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Finland, Turku
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Sweden, SOLNA
Type: Company (for-profit)
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
Sweden, UPPSALA
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
Norway, Oslo
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 sectors.
